Investigation of the antitumor effects of anti-inflammatory desloratadine and trimebutine on different types of human cancer cells: An in vitro study

ÖZKAYA, Semiha Nur; Keskin, Tuba; TEKIN, CİGDEM; Tekin, Suat; BEYTUR, ALİ

doi:10.5455/annalsmedres.2023.05.122

Investigation of the antitumor effects of anti-inflammatory desloratadine and trimebutine on different types of human cancer cells: An in vitro study

Semiha Nur ÖZKAYA, (İnönü Üniversitesi, Tıp Fakültesi, Fizyoloji Anabilim Dalı, Malatya, Türkiye)

Tuba KESKİN, (İnönü Üniversitesi, Tıp Fakültesi, Fizyoloji Anabilim Dalı, Malatya, Türkiye)

Çiğdem TEKİN, (İnönü Üniversitesi, Sağlık Hizmetleri Meslek Yüksekokulu, Sağlık Hizmetleri Anabilim Dalı, Malatya, Türkiye)

Suat TEKİN, (İnönü Üniversitesi, Tıp Fakültesi, Fizyoloji Anabilim Dalı, Malatya, Türkiye)

Ali BEYTUR (İnönü Üniversitesi, Tıp Fakültesi, Üroloji Anabilim Dalı, Malatya, Türkiye)

Annals of Medical Research

21 3

Yıl: 2023 Cilt: 30 Sayı: 6 Sayfa Aralığı: 727 - 732 Metin Dili: İngilizce DOI: 10.5455/annalsmedres.2023.05.122 İndeks Tarihi: 25-07-2023

Investigation of the antitumor effects of anti-inflammatory desloratadine and trimebutine on different types of human cancer cells: An in vitro study

Öz:

Aim: Inflammation is a process associated with the development and progression of cancer. Desloratadine (DES) and Trimebutin (TMB) are anti-inflammatory agents used in the treatment of various diseases. This study aimed to investigate the antitumor effects of DES and TMB, which exhibit anti-inflammatory effects, on different human cancer cell lines. Materials and Methods: In this study, human prostate (LNCaP), ovarian (A2780), breast (MCF-7) and colon cancer (Caco-2) cell lines were treated with DES and TMB at concentrations of 1, 5, 25, 50 and 100 µM. Cells were treated with the compounds for 6, 12, and 24 hours, and the change in cell viability was determined using the 3- (4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The inhibitory concentration 50 (LogIC50) values of the compounds were calculated using GraphPad Prism 8 software based on cell viability results. The genotoxic effects of the compounds on cells were determined using the comet assay. Group comparisons were performed using the Kruskal-Wallis H test and p<0.05 was considered significant. Results: Exposure of LNCaP, A2780, MCF-7, and Caco-2 cells to DES and TMB agents for 6, 12 and 24 hours significantly reduced cell viability (p<0.05). According to the comet assay results, DES and TMB caused significant DNA damage in the cell lines (p<0.05). Conclusion: The study results demonstrate that DES and TMB, which have anti inflammatory effects, exert cytotoxic effects by inducing DNA damage in cancer cells.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71(1):7-33.
2. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statis tics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
3. Beeram M, Patnaik A, Rowinsky EK. Raf: a strategic tar get for therapeutic development against cancer. J Clin Oncol. 2005;23(27):6771-90.
4. Zhang C, Liu J, Xu D, et al. Gain-of-function mutant p53 in cancer progression and therapy. J Mol Cell Biol. 2020;12(9):674- 87.
5. Cagnol S, Chambard J-C. ERK and cell death: Mechanisms of ERK-induced cell death – apoptosis, autophagy and senescence. The FEBS journal. 2010;277(1):2-21.
6. Xu JC, Chen TY, Liao LT, et al. NETO2 promotes esophageal cancer progression by inducing proliferation and metastasis via PI3K/AKT and ERK pathway. Int J Biol Sci. 2021;17(1):259-70.
7. Zappavigna S, Cossu AM, Grimaldi A, et al. Anti-inflammatory drugs as anticancer agents. Int J Mol Sci. 2020;21(7):2605.
8. Jemel-Oualha I, Elloumi-Mseddi J, Beji A, et al. Controversial effect on Erk activation of some cytotoxic drugs in human LOVO colon cancer cells. J Recept Signal Transduct Res. 2016;36(1):21- 25.
9. Chen M, Xu S, Zhou P, et al. Desloratadine citrate disodium injection, a potent histamine H1 receptor antagonist, inhibits chemokine production in ovalbumin-induced allergic rhinitis guinea pig model and histamine-induced human nasal epithelial cells via inhibiting the ERK1/2 and NF-kappa B signal cascades. Eur J Pharmacol. 2015;767:98-107.
10. Anthes JC, Gilchrest H, Richard C, et al. Biochemical charac terization of desloratadine, a potent antagonist of the human histamine H1 receptor. Eur J Pharmacol. 2002;449(3):229-37.
11. Söldner CA, Horn AH, Sticht H. Binding of histamine to the H1 receptor—A molecular dynamics study. J Mol Model. 2018;24(12):1-16.
12. Khadeer S, Jagannath B. Comparison of efficacy and tolerabil ity of oral desloratadine, rupatadine and ketotifen in seasonal allergic rhinitis. IP Journal of Otorhinolaryngology and Allied Science. 2021;4:106-14.
13. Forough AS, Fakharian A, Joubani SF, et al. The clinical efficacy of desloratadine, a non-sedating antihistamine, in the manage ment of allergic conditions: A review of the evidence. Bulletin of Pharmaceutical Sciences Assiut. 2021;44(2):477-510.
14. Kleine-Tebbe J, Josties C, Frank G, et al. Inhibition of IgE-and non-IgE-mediated histamine release from human basophil leuko cytes in vitro by a histamine H1-antagonist, desethoxycarbonyl loratadine. J Allergy Clin Immunol. 1994;93(2):494-500.
15. Wu RLA, John C Kreutner, William Harris, et al. Desloratadine inhibits constitutive and histamine-stimulated nuclear factor-κB activity consistent with inverse agonism at the histamine H1 receptor. Int Arch Allergy Immunol 2004;135(4):313-18.
16. Schroeder J, Schleimer R, Lichtenstein L, Kreutner W. In hibition of cytokine generation and mediator release by hu man basophils treated with desloratadine. Clin Exp Allergy. 2001;31(9):1369-77.
17. Lippert U, Krüger-Krasagakes S, Möller A, et al. Pharmacolog ical modulation of IL-6 and IL-8 secretion by the H1-antagonist decarboethoxy-loratadine and dexamethasone by human mast and basophilic cell lines. Exp Dermatol. 1995;4(4):272-76.
18. Delvaux M, Wingate D. Trimebutine: mechanism of action, ef fects on gastrointestinal function and clinical results. J Int Med Res. 1997;25(5):225-46.
19. Tan W, Zhang H, Luo HS, Xia H. Effects of trimebutine maleate on colonic motility through Ca2+-activated K+ channels and L type Ca2+ channels. Arch Pharm Res. 2011;34(6):979-85.
20. Masaaki N, Tsutomu K, Hajime T. Effects of trimebutine on cytosolic Ca2+ and force transitions in intestinal smooth muscle. Eur J Pharmacol. 1991;195(3):317-21.
21. Lacheze C, Coelho A, Fioramonti J, Bueno L. Influence of trime butine on inflammation and stress induced hyperalgesia to rectal distension in rats. J Pharm Pharmacol. 1998;50(8):921-28.
22. Koyunoğlu F, Tekin S, Konar V, Sandal S. İnsan meme kanseri hücre serileri (mcf-7) üzerine apelin-13’ün etkilerinin araştırıl ması: ın vitro bir çalışma. İnönü Üniversitesi Sağlık Bilimleri Dergisi. 2013.
23. Tekin S, Erden Y, Sandal S, Yilmaz B. Is irisin an anticarcino genic peptide? Medicine Science. 2015;4(2):2172-80.
24. Denizot F, Lang R. Rapid colorimetric assay for cell growth and survival: modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods. 1986;89(2):271-77.
25. Horáková Kn, Šovč´ıková A, Seemannová Z, et al. Detection of drug-induced, superoxide-mediated cell damage and its preven tion by antioxidants. Free Radic Biol Med. 2001;30(6):650-64.
26. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65(1-2):55-63.
27. Koran K, Tekin Ç, Çalışkan E, et al. Synthesis, structural and thermal characterizations and in vitro cytotoxic activities of new cyclotriphosphazene derivatives. Phosphorus, Sulfur, Silicon the Related Elements. 2017;192(9):1002-11.
28. Klaude M, Eriksson S, Nygren J, Ahnström G. The comet assay: mechanisms and technical considerations. Mutat Res. 1996;363(2):89-96.
29. Devlin HL, Mack PC, Burich RA, et al. Impairment of the DNA repair and growth arrest pathways by p53R2 silencing enhances DNA damage–induced apoptosis in a p53-dependent manner in prostate cancer cells. Mol Cancer Res. 2008;6(5):808-18.
30. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA: A Cancer Journal for Clinicians. 2023;73(1):17-48.
31. Passaro A, Brahmer J, Antonia S, et al. Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022;40(6):598-610.
32. Stoletov K, Beatty PH, Lewis JD. Novel therapeutic targets for cancer metastasis. Expert review of anticancer therapy. 2020;20(2):97-109.
33. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436-44.
34. Suarez-Carmona M, Lesage J, Cataldo D, Gilles C. EMT and in flammation: inseparable actors of cancer progression. Molecular oncology. 2017;11(7):805-23.
35. Baron JA, Sandler RS. Nonsteroidal anti-inflammatory drugs and cancer prevention. Annual review of medicine. 2000;51:511- 23.
36. Fritz I, Wagner P, Broberg P, et al. Desloratadine and loratadine stand out among common H1-antihistamines for association with improved breast cancer survival. Acta Oncol. 2020;59(9):1103- 09.
37. Ma J, Qi J, Li S, et al. Desloratadine, a novel antigrowth reagent for bladder cancer. Technol Cancer Res Treat. 2020;19:1-19.
38. Fan YP, Liu P, Xue WK, et al. Trimebutine promotes glioma cell apoptosis as a potential anti-tumor agent. Front Pharmacol. 2018;9:664.
39. Erden Y. Capsanthin Stimulates the Mitochondrial Apoptosis Mediated Cell Death, following DNA Damage in MCF-7 Cells. Nutrition and cancer. 2021;73(4):662-70.

APA	ÖZKAYA S, Keskin T, TEKIN C, Tekin S, BEYTUR A (2023). Investigation of the antitumor effects of anti-inflammatory desloratadine and trimebutine on different types of human cancer cells: An in vitro study. , 727 - 732. 10.5455/annalsmedres.2023.05.122
Chicago	ÖZKAYA Semiha Nur,Keskin Tuba,TEKIN CİGDEM,Tekin Suat,BEYTUR ALİ Investigation of the antitumor effects of anti-inflammatory desloratadine and trimebutine on different types of human cancer cells: An in vitro study. (2023): 727 - 732. 10.5455/annalsmedres.2023.05.122
MLA	ÖZKAYA Semiha Nur,Keskin Tuba,TEKIN CİGDEM,Tekin Suat,BEYTUR ALİ Investigation of the antitumor effects of anti-inflammatory desloratadine and trimebutine on different types of human cancer cells: An in vitro study. , 2023, ss.727 - 732. 10.5455/annalsmedres.2023.05.122
AMA	ÖZKAYA S,Keskin T,TEKIN C,Tekin S,BEYTUR A Investigation of the antitumor effects of anti-inflammatory desloratadine and trimebutine on different types of human cancer cells: An in vitro study. . 2023; 727 - 732. 10.5455/annalsmedres.2023.05.122
Vancouver	ÖZKAYA S,Keskin T,TEKIN C,Tekin S,BEYTUR A Investigation of the antitumor effects of anti-inflammatory desloratadine and trimebutine on different types of human cancer cells: An in vitro study. . 2023; 727 - 732. 10.5455/annalsmedres.2023.05.122
IEEE	ÖZKAYA S,Keskin T,TEKIN C,Tekin S,BEYTUR A "Investigation of the antitumor effects of anti-inflammatory desloratadine and trimebutine on different types of human cancer cells: An in vitro study." , ss.727 - 732, 2023. 10.5455/annalsmedres.2023.05.122
ISNAD	ÖZKAYA, Semiha Nur vd. "Investigation of the antitumor effects of anti-inflammatory desloratadine and trimebutine on different types of human cancer cells: An in vitro study". (2023), 727-732. https://doi.org/10.5455/annalsmedres.2023.05.122

APA	ÖZKAYA S, Keskin T, TEKIN C, Tekin S, BEYTUR A (2023). Investigation of the antitumor effects of anti-inflammatory desloratadine and trimebutine on different types of human cancer cells: An in vitro study. Annals of Medical Research, 30(6), 727 - 732. 10.5455/annalsmedres.2023.05.122
Chicago	ÖZKAYA Semiha Nur,Keskin Tuba,TEKIN CİGDEM,Tekin Suat,BEYTUR ALİ Investigation of the antitumor effects of anti-inflammatory desloratadine and trimebutine on different types of human cancer cells: An in vitro study. Annals of Medical Research 30, no.6 (2023): 727 - 732. 10.5455/annalsmedres.2023.05.122
MLA	ÖZKAYA Semiha Nur,Keskin Tuba,TEKIN CİGDEM,Tekin Suat,BEYTUR ALİ Investigation of the antitumor effects of anti-inflammatory desloratadine and trimebutine on different types of human cancer cells: An in vitro study. Annals of Medical Research, vol.30, no.6, 2023, ss.727 - 732. 10.5455/annalsmedres.2023.05.122
AMA	ÖZKAYA S,Keskin T,TEKIN C,Tekin S,BEYTUR A Investigation of the antitumor effects of anti-inflammatory desloratadine and trimebutine on different types of human cancer cells: An in vitro study. Annals of Medical Research. 2023; 30(6): 727 - 732. 10.5455/annalsmedres.2023.05.122
Vancouver	ÖZKAYA S,Keskin T,TEKIN C,Tekin S,BEYTUR A Investigation of the antitumor effects of anti-inflammatory desloratadine and trimebutine on different types of human cancer cells: An in vitro study. Annals of Medical Research. 2023; 30(6): 727 - 732. 10.5455/annalsmedres.2023.05.122
IEEE	ÖZKAYA S,Keskin T,TEKIN C,Tekin S,BEYTUR A "Investigation of the antitumor effects of anti-inflammatory desloratadine and trimebutine on different types of human cancer cells: An in vitro study." Annals of Medical Research, 30, ss.727 - 732, 2023. 10.5455/annalsmedres.2023.05.122
ISNAD	ÖZKAYA, Semiha Nur vd. "Investigation of the antitumor effects of anti-inflammatory desloratadine and trimebutine on different types of human cancer cells: An in vitro study". Annals of Medical Research 30/6 (2023), 727-732. https://doi.org/10.5455/annalsmedres.2023.05.122